Roivant Sciences, the parent company of the “Vant” family of biotechs, has secured a massive $1.1 billion investment.
Biotech VC Jonathan Silverstein has unveiled the next development in his quest to find a cure for Parkinson's with GBA.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
The agreement brings together two of the biotechs plugging away, with mixed success, at late-phase development of anti-infective drugs.
Here's Wednesday's prescription for your biopharma news of note.
Ardelyx is cutting its workforce by nearly one-third as it looks to sharpen its focus on its phase 3 candidates.
Here's Tuesday's dose of your biopharma news of note.
Dermira will take on certain rights to lebrikizumab from Roche.
The deal gives Sellas a route to public investors as it seeks to guide its WT1-targeting drug through phase 3 trials in AML and mesothelioma.
BMS will pay $300 million up front and up to $2 billion in biobucks for IFM Therapeutics.
GlaxoSmithKline confirms that it will be shutting down operations at its Shanghai R&D base as it looks west.